We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

1 hedge funds and large institutions have $435K invested in Array Biopharma Inc in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PAA
Peregrine Asset Advisers
Oregon
+$435K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
PAA
1
Peregrine Asset Advisers
Oregon
$435K +$435K +10,094 New

ARRY Hedge Fund Activity: Q4 2020 in Review

1 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q4 2020, worth a combined $435K.

Buyers outnumbered sellers: 1 fund opened new ARRY positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Peregrine Asset Advisers, opening a new position worth an estimated $435K.

  • 1 institutional investor held Array Biopharma Inc (ARRY) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $435K of Array Biopharma Inc stock for Q4 2020.
  • 1 fund opened new Array Biopharma Inc positions in Q4 2020 and 0 closed out, a net change of +1 holder.
  • The largest Array Biopharma Inc buyer in Q4 2020 was Peregrine Asset Advisers, an estimated $435K added.

Based on aggregated 13F filings for Q4 2020.